Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Cryptococcosis | Research

Pulmonary cryptococcosis complicated with pulmonary aspergillosis: a series of studies and a literature review

Authors: Xidong Wang, Shaoqiang Li, Mangui Zhu, Ye Qiu, Yilei Hui, Yongming Li, Yangqing Zhan, Yan Wang, Feng Ye, Zhengtu Li

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background/Objective

With the development of society, pulmonary fungal diseases, represented by pulmonary aspergillosis and pulmonary cryptococcosis, have become increasingly common. However, there is a lack of clear understanding regarding coinfection by these two types of fungi in immunocompetent individuals.

Methods

A retrospective study from 2014 to 2022 and a systematic literature review of original articles published in English were performed. Patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis including 5 in the retrospective study and 6 in the systematic literature review.

Result

The diagnosis of concurrent pulmonary cryptococcosis and pulmonary aspergillosis in patients was confirmed through repeated biopsies or surgical resection. Pulmonary cryptococcosis is often diagnosed initially (6/11, 55%), while the diagnosis of pulmonary aspergillosis is established when the lesions become fixed or enlarged during treatment. Transbronchial lung biopsy (3/11, 27%), thoracoscopic lung biopsy (2/11, 18%), and percutaneous aspiration biopsy of the lung (1/11, 9%) were the main methods to confirm concurrent infection. Most patients were treated with voriconazole, resulting in a cure for the coinfection (6/11, 55%).

Conclusion

Pulmonary cryptococcosis complicated with pulmonary Aspergillus is an easily neglected mixed fungal infection. During the treatment of lesion enlargement in clinical cryptococcus, we need to watch out for Aspergillus infection.
Literature
1.
go back to reference Wheeler ML, Limon JJ, Underhill DM. Immunity to commensal fungi: Detente and disease [J]. Annu Rev Pathol. 2017;12:359–85.CrossRefPubMed Wheeler ML, Limon JJ, Underhill DM. Immunity to commensal fungi: Detente and disease [J]. Annu Rev Pathol. 2017;12:359–85.CrossRefPubMed
2.
go back to reference Bongomin F, Gago S, Oladele RO et al. Global and multi-national prevalence of fungal diseases-estimate precision [J]. J Fungi (Basel), 2017, 3(4). Bongomin F, Gago S, Oladele RO et al. Global and multi-national prevalence of fungal diseases-estimate precision [J]. J Fungi (Basel), 2017, 3(4).
3.
go back to reference Who releases first-. Ever list of health-threatening fungi [J]. Saudi Med J. 2022;43(11):1284–5. Who releases first-. Ever list of health-threatening fungi [J]. Saudi Med J. 2022;43(11):1284–5.
4.
go back to reference Loughlin L, Hellyer TP, White PL, et al. Pulmonary aspergillosis in patients with suspected ventilator-associated pneumonia in Uk icus [J]. Am J Respir Crit Care Med. 2020;202(8):1125–32.CrossRefPubMedPubMedCentral Loughlin L, Hellyer TP, White PL, et al. Pulmonary aspergillosis in patients with suspected ventilator-associated pneumonia in Uk icus [J]. Am J Respir Crit Care Med. 2020;202(8):1125–32.CrossRefPubMedPubMedCentral
5.
go back to reference Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study [J]. J Infect. 2010;61(5):419–26.CrossRefPubMed Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study [J]. J Infect. 2010;61(5):419–26.CrossRefPubMed
6.
go back to reference Awari DW, Shah AS, Sexton AM et al. Coinfection of aspergillus and cryptococcus in immunocompromised host: A case report and review of literature [J]. Case Rep Infect Dis, 2020, 2020: 8888270. Awari DW, Shah AS, Sexton AM et al. Coinfection of aspergillus and cryptococcus in immunocompromised host: A case report and review of literature [J]. Case Rep Infect Dis, 2020, 2020: 8888270.
7.
go back to reference Wang Q, Wang Z, Hao Y, et al. Coinfection with cryptococcus and aspergillus in an immunocompetent adult: a case report [J]. Med (Baltim). 2018;97(39):e12612.CrossRef Wang Q, Wang Z, Hao Y, et al. Coinfection with cryptococcus and aspergillus in an immunocompetent adult: a case report [J]. Med (Baltim). 2018;97(39):e12612.CrossRef
8.
go back to reference Kimura M, Maenishi O, Enoki E, et al. Aspergillus fungal ball in central cavity of a pulmonary cryptococcal nodal lesion [J]. Pathol Int. 2015;65(6):329–31.CrossRefPubMed Kimura M, Maenishi O, Enoki E, et al. Aspergillus fungal ball in central cavity of a pulmonary cryptococcal nodal lesion [J]. Pathol Int. 2015;65(6):329–31.CrossRefPubMed
9.
go back to reference Enoki E, Maenishi O, Chikugo T, et al. Coinfection of aspergillus and cryptococcus in post-tuberculosis pulmonary cavity [J]. Pathol Int. 2012;62(8):574–6.CrossRefPubMed Enoki E, Maenishi O, Chikugo T, et al. Coinfection of aspergillus and cryptococcus in post-tuberculosis pulmonary cavity [J]. Pathol Int. 2012;62(8):574–6.CrossRefPubMed
10.
go back to reference Lin CM, Tsai YH, Huang CC, et al. Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host [J]. J Infect. 2006;53(2):e55–8.CrossRefPubMed Lin CM, Tsai YH, Huang CC, et al. Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host [J]. J Infect. 2006;53(2):e55–8.CrossRefPubMed
11.
go back to reference Rosenheim SH, Schwarz J. Cavitary pulmonary cryptococcosis complicated by aspergilloma [J]. Am Rev Respir Dis. 1975;111(4):549–53.PubMed Rosenheim SH, Schwarz J. Cavitary pulmonary cryptococcosis complicated by aspergilloma [J]. Am Rev Respir Dis. 1975;111(4):549–53.PubMed
12.
go back to reference Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium [J]. Clin Infect Dis. 2020;71(6):1367–76.CrossRefPubMed Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium [J]. Clin Infect Dis. 2020;71(6):1367–76.CrossRefPubMed
13.
go back to reference Warris A. The biology of pulmonary aspergillus infections [J]. J Infect. 2014;69(Suppl 1):36–41.CrossRef Warris A. The biology of pulmonary aspergillus infections [J]. J Infect. 2014;69(Suppl 1):36–41.CrossRef
14.
go back to reference Raju S, Ghosh S, Mehta AC. Chest ct signs in pulmonary disease: a pictorial review [J]. Chest. 2017;151(6):1356–74.CrossRefPubMed Raju S, Ghosh S, Mehta AC. Chest ct signs in pulmonary disease: a pictorial review [J]. Chest. 2017;151(6):1356–74.CrossRefPubMed
15.
go back to reference Sui X, Huang Y, Song W, et al. Clinical features of pulmonary cryptococcosis in thin-section ct in immunocompetent and non-aids immunocompromised patients [J]. Radiol Med. 2020;125(1):31–8.CrossRefPubMed Sui X, Huang Y, Song W, et al. Clinical features of pulmonary cryptococcosis in thin-section ct in immunocompetent and non-aids immunocompromised patients [J]. Radiol Med. 2020;125(1):31–8.CrossRefPubMed
16.
go back to reference Mondoni M, Rinaldo RF, Carlucci P, et al. Bronchoscopic sampling techniques in the era of technological bronchoscopy [J]. Pulmonology. 2022;28(6):461–71.CrossRefPubMed Mondoni M, Rinaldo RF, Carlucci P, et al. Bronchoscopic sampling techniques in the era of technological bronchoscopy [J]. Pulmonology. 2022;28(6):461–71.CrossRefPubMed
17.
go back to reference Lee SM, Park CM, Lee KH, et al. C-arm cone-beam ct-guided percutaneous transthoracic needle biopsy of lung nodules: clinical experience in 1108 patients [J]. Radiology. 2014;271(1):291–300.CrossRefPubMed Lee SM, Park CM, Lee KH, et al. C-arm cone-beam ct-guided percutaneous transthoracic needle biopsy of lung nodules: clinical experience in 1108 patients [J]. Radiology. 2014;271(1):291–300.CrossRefPubMed
18.
go back to reference Zilberberg MD, Harrington R, Spalding JR, et al. Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004–2013 [J]. BMC Public Health. 2019;19(1):591.CrossRefPubMedPubMedCentral Zilberberg MD, Harrington R, Spalding JR, et al. Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004–2013 [J]. BMC Public Health. 2019;19(1):591.CrossRefPubMedPubMedCentral
19.
go back to reference Douglas AP, Smibert OC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021 [J]. Intern Med J. 2021;51(Suppl 7):143–76.CrossRefPubMed Douglas AP, Smibert OC, Bajel A, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021 [J]. Intern Med J. 2021;51(Suppl 7):143–76.CrossRefPubMed
20.
go back to reference Malani AN, Kerr LE, Kauffman CA, Voriconazole. How to use this antifungal agent and what to expect [J]. Semin Respir Crit Care Med. 2015;36(5):786–95.CrossRefPubMed Malani AN, Kerr LE, Kauffman CA, Voriconazole. How to use this antifungal agent and what to expect [J]. Semin Respir Crit Care Med. 2015;36(5):786–95.CrossRefPubMed
21.
go back to reference Silva EG, Paula CR, de Assis Baroni F, et al. Voriconazole, combined with amphotericin b, in the treatment for pulmonary cryptococcosis caused by c. Neoformans (serotype a) in mice with severe combined immunodeficiency (scid) [J]. Mycopathologia. 2012;173(5–6):445–9.CrossRefPubMed Silva EG, Paula CR, de Assis Baroni F, et al. Voriconazole, combined with amphotericin b, in the treatment for pulmonary cryptococcosis caused by c. Neoformans (serotype a) in mice with severe combined immunodeficiency (scid) [J]. Mycopathologia. 2012;173(5–6):445–9.CrossRefPubMed
22.
go back to reference Zhao T, Xu X, Wu Y, et al. Comparison of amphotericin b deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of hiv-associated cryptococcal meningitis: a prospective multicenter study in China [J]. BMC Infect Dis. 2022;22(1):677.CrossRefPubMedPubMedCentral Zhao T, Xu X, Wu Y, et al. Comparison of amphotericin b deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of hiv-associated cryptococcal meningitis: a prospective multicenter study in China [J]. BMC Infect Dis. 2022;22(1):677.CrossRefPubMedPubMedCentral
23.
go back to reference Fujioka K, Nagai T, Kinoshita Y, et al. Successful treatment with voriconazole combined with amphotericin b-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation [J]. CEN Case Rep. 2019;8(4):261–5.CrossRefPubMedPubMedCentral Fujioka K, Nagai T, Kinoshita Y, et al. Successful treatment with voriconazole combined with amphotericin b-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation [J]. CEN Case Rep. 2019;8(4):261–5.CrossRefPubMedPubMedCentral
24.
go back to reference Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy [J]. Nat Rev Neurol. 2017;13(1):13–24.CrossRefPubMed Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy [J]. Nat Rev Neurol. 2017;13(1):13–24.CrossRefPubMed
25.
go back to reference Who guidelines approved by the guidelines review committee [M]. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with hiv. Geneva; © World Health Organization; 2022. Who guidelines approved by the guidelines review committee [M]. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with hiv. Geneva; © World Health Organization; 2022.
26.
go back to reference Smith KD, Achan B, Hullsiek KH, et al. Increased antifungal drug resistance in clinical isolates of cryptococcus neoformans in Uganda [J]. Antimicrob Agents Chemother. 2015;59(12):7197–204.CrossRefPubMedPubMedCentral Smith KD, Achan B, Hullsiek KH, et al. Increased antifungal drug resistance in clinical isolates of cryptococcus neoformans in Uganda [J]. Antimicrob Agents Chemother. 2015;59(12):7197–204.CrossRefPubMedPubMedCentral
27.
go back to reference Naicker SD, Mpembe RS, Maphanga TG, et al. Decreasing fluconazole susceptibility of clinical South African cryptococcus neoformans isolates over a decade [J]. PLoS Negl Trop Dis. 2020;14(3):e0008137.CrossRefPubMedPubMedCentral Naicker SD, Mpembe RS, Maphanga TG, et al. Decreasing fluconazole susceptibility of clinical South African cryptococcus neoformans isolates over a decade [J]. PLoS Negl Trop Dis. 2020;14(3):e0008137.CrossRefPubMedPubMedCentral
28.
go back to reference Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects [J]. Med Mycol. 2019;57(2):133–50.CrossRefPubMed Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects [J]. Med Mycol. 2019;57(2):133–50.CrossRefPubMed
Metadata
Title
Pulmonary cryptococcosis complicated with pulmonary aspergillosis: a series of studies and a literature review
Authors
Xidong Wang
Shaoqiang Li
Mangui Zhu
Ye Qiu
Yilei Hui
Yongming Li
Yangqing Zhan
Yan Wang
Feng Ye
Zhengtu Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09014-8

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.